| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/09/2009 | WO2009043520A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | WO2009043519A2 Use of band 3 protein and pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043507A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043506A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043505A2 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer |
| 04/09/2009 | WO2009043504A2 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer |
| 04/09/2009 | WO2009043481A2 Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043479A2 Use of eaa-mart1 (26-35) for the treatment of human cytomegalovirus infections |
| 04/09/2009 | WO2009043478A2 Use of bubuc and optionally eaa-mart1 (26-35) as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043469A2 Use of pneumadin as a therapeutic agent |
| 04/09/2009 | WO2009043467A1 U e of urocortin and corticotropin-releasing fact r as therapeutic agents |
| 04/09/2009 | WO2009043466A2 Therapeutic use of the peptide gluten exorphin a5 |
| 04/09/2009 | WO2009043465A2 Use of beta-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043463A2 Use of gluten exorphin c : as a therapeutic agent |
| 04/09/2009 | WO2009043462A1 Use of neuropeptide af as a therapeutic agent |
| 04/09/2009 | WO2009043461A1 Use of a hnp-1 defensin peptide, alone or in combination with neuropeptide af, as a therapeutic agent |
| 04/09/2009 | WO2009043460A1 Use of alpha-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043459A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | WO2009043458A2 Use of oxytocin to treat many diseases |
| 04/09/2009 | WO2009043457A2 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis |
| 04/09/2009 | WO2009043456A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043455A2 Therapeutic uses of angiogenin 108-122 and gluten exorphin a5 |
| 04/09/2009 | WO2009043454A2 Use of pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043453A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043452A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | WO2009043449A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043447A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043441A1 D-ala-gln-octadecyl ester as a therapeutic agent |
| 04/09/2009 | WO2009043440A2 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
| 04/09/2009 | WO2009043439A2 Use of retrocyclin- 1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043437A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/09/2009 | WO2009043436A2 Use of af12198 as a therapeutic agent |
| 04/09/2009 | WO2009043171A1 Method of regulating the th17 pathway and its associated metabolic impact |
| 04/09/2009 | WO2009043155A2 Distinct hiv-1 gag and env epitopes of hla alleles associated with differential susceptibility to hiv-1 infection |
| 04/09/2009 | WO2009043117A1 Novel aryl potassium channel blockers and uses thereof |
| 04/09/2009 | WO2009043116A1 Methods and compositions for the treatment of phosphatase- related disorders |
| 04/09/2009 | WO2009004094A3 Compounds and methods for the treatment of renal disease |
| 04/09/2009 | WO2008138943A3 Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies |
| 04/09/2009 | WO2008106200A3 Human anti-ip-10 antibodies and uses thereof |
| 04/09/2009 | US20090093639 Prodrugs of carbamate inhibitors of IMPDH |
| 04/09/2009 | US20090093617 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 04/09/2009 | US20090093501 Heterocyclic antiviral compounds |
| 04/09/2009 | US20090093478 N-aroyl cyclic amines |
| 04/09/2009 | US20090093476 Pyrrolo[1,2-a]quinoxaline derivatives as adenosine a3 receptor modulators and uses thereof |
| 04/09/2009 | US20090093475 Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals |
| 04/09/2009 | US20090093405 Non-Natural Amino Acid Polypeptides Having Modified Immunogenicity |
| 04/09/2009 | US20090092637 Medicaments and methods to treat autoimmune disease and cancer |
| 04/09/2009 | US20090092635 Heterologous prime-boost immunization regimen |
| 04/09/2009 | US20090092631 Glycosylated specificity exchangers that induce an antibody dependent cellular cytotoxicity (adcc) response |
| 04/09/2009 | US20090092611 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092605 Compositions and methods for the treatment of immune related diseases |
| 04/09/2009 | US20090092592 Methionyl tRNA Synthetase Polynucleotides |
| 04/09/2009 | US20090092545 Antibodies that bind both bcma and taci |
| 04/09/2009 | DE102007046086A1 Pflanzenextrakt aus THC-armen Cannabis zur Behandlung von Erkrankungen Plant extract of low-THC cannabis in treating diseases |
| 04/09/2009 | CA2734139A1 Antibody therapy for use in the digestive tract |
| 04/09/2009 | CA2710406A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2701778A1 Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| 04/09/2009 | CA2701719A1 Dry powders of cellular material |
| 04/09/2009 | CA2701579A1 Novel aryl potassium channel blockers and uses thereof |
| 04/09/2009 | CA2701494A1 Method of regulating the th17 pathway and its associated metabolic impact |
| 04/09/2009 | CA2701406A1 Benzoxazinone derivative |
| 04/09/2009 | CA2701172A1 Methods of treating neurological autoimmune disorders with cyclophosphamide |
| 04/09/2009 | CA2701155A1 Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient |
| 04/09/2009 | CA2700963A1 Oxypiperidine derivatives and methods of use thereof |
| 04/09/2009 | CA2699264A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | CA2699260A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699255A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699114A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699113A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699109A1 Use of urocortin and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699107A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | CA2699105A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699104A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699078A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699074A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699067A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | CA2698690A1 Thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | CA2698688A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2698687A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2696863A1 Oxadiazole derivatives |
| 04/09/2009 | CA2696829A1 Oxadiazole diaryl compounds |
| 04/08/2009 | EP2045244A1 Novel crystal of substituted phenylalkanoic acid and production process |
| 04/08/2009 | EP2045242A1 Heterocyclic compounds having inhibitory activity against HIV integrase |
| 04/08/2009 | EP2045241A1 Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists |
| 04/08/2009 | EP2044957A1 Treatment agent for inflammatory bowel disease |
| 04/08/2009 | EP2044950A2 Attenuated VIF DNA immunization cassettes for genetic vaccines |
| 04/08/2009 | EP2044949A1 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| 04/08/2009 | EP2044945A1 Immunomodulating agent |
| 04/08/2009 | EP2044851A1 Prevention of allergy at weaning |
| 04/08/2009 | EP2044197A1 Method of producing a population of cells |
| 04/08/2009 | EP2044118A2 Il-17 and il-23 antagonists and methods of using the same |
| 04/08/2009 | EP2044100A2 Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| 04/08/2009 | EP2044071A1 OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS |
| 04/08/2009 | EP2044046A2 Substituted n-acyl homoserine lactones |
| 04/08/2009 | EP2044027A2 Fused bicyclic compounds interacting with the histamine h4 receptor |
| 04/08/2009 | EP2043686A2 Antagonists of protease activated receptor-1 (par1) |
| 04/08/2009 | EP2043673A2 Use of soluble cd160 to suppress immunity |
| 04/08/2009 | EP2043655A2 Purine and deazapurine derivatives as pharmaceutical compounds |
| 04/08/2009 | EP2043629A1 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases |
| 04/08/2009 | EP1461015B1 Compositions containing both sedative and non-sedative antihistamines |